Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Moderna Q3 EPS $(0.51) Beats $(2.02) Estimate, Sales $1.016B Beat $886.539M Estimate

Author: Benzinga Newsdesk | November 06, 2025 07:02am
Moderna (NASDAQ:MRNA) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(2.02) by 74.73 percent. This is a 1800 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $1.016 billion which beat the analyst consensus estimate of $886.539 million by 14.60 percent. This is a 45.44 percent decrease over sales of $1.862 billion the same period last year.

Posted In: MRNA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist